Announcements Trials
Browse Landscape

Phase

Phase 1 4Phase 3 3Phase 1/2 3Phase 2 2

Status

Terminated 2Completed 1

Sponsor Class

INDUSTRY 3

Study Type

Interventional 3

Sponsor

Cancer Type

Thoracic 2Dermatologic 1CNS 1

Conditions

Small Cell Lung Carcinoma 2Neoplasms 1Melanoma 1Glioblastoma 1Carcinoma, Medullary 1

Interventions

pembrolizumab 409Cyclophosphamide 398Carboplatin 307Gemcitabine 286Nivolumab 276Paclitaxel 274Cisplatin 252Radiotherapy 225Dexamethasone 209Bevacizumab 207fludarabine 195Docetaxel 186Rituximab 183Capecitabine 171Oxaliplatin 158Lenalidomide 157Fluorouracil 152Temozolomide 138Cytarabine 135Etoposide 128Irinotecan 124Cetuximab 123fludarabine phosphate 121Injections 118venetoclax 116Ipilimumab 115Doxorubicin 114Azacitidine 108130-nm albumin-bound paclitaxel 108Pemetrexed 107

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 1/2 × Interventional × rovalpituzumab tesirine × Clear all
NCT02709889 2020-10-19

Rovalpituzumab Tesirine in Delta-Like Protein 3-Expressing Advanced Solid Tumors

AbbVie

Phase 1/2 Terminated
200 enrolled 21 charts
CNSDermatologic

Glioblastoma, Melanoma, Carcinoma, Medullary

NCT03026166 2020-07-17

A Study of Rovalpituzumab Tesirine Administered in Combination With Nivolumab and With or Without Ipilimumab for Adults With Extensive-Stage Small Cell Lung Cancer

AbbVie

Phase 1/2 Terminated
42 enrolled 15 charts
Thoracic

Neoplasms, Small Cell Lung Carcinoma

NCT01901653 2018-08-09

Rovalpituzumab Tesirine (SC16LD6.5) in Recurrent Small Cell Lung Cancer

Stemcentrx

Phase 1/2 Completed
82 enrolled 28 charts
Thoracic

Small Cell Lung Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡